LEPTIN AND HEMATOPOIESIS

Information

• Research Project
• 2332572

• ApplicationId

  2332572

• Core Project Number

  R43HL058415

• Full Project Number

  1R43HL058415-01

• Serial Number

  58415

• FOA Number

• Sub Project Id

• Project Start Date

  9/30/1997 - 26 years ago

• Project End Date

  3/29/1998 - 26 years ago

• Program Officer Name

• Budget Start Date

  9/30/1997 - 26 years ago

• Budget End Date

  3/29/1998 - 26 years ago

• Fiscal Year

  1997

• Support Year

  1

• Suffix

• Award Notice Date

  9/26/1997 - 26 years ago

Organizations

• ICOGENEX CORPORATION

DESCRIPTION: (Adapted from the Applicant's Abstract): The goal of this project is to develop therapeutic applications for leptin in treatment of hematopoietic diseases and transplantation. Recently they have found that leptin affects the survival and expansion of a population of bone marrow cells. A thorough characterization of the effect of leptin on fractionated bone marrow cells will be performed. The lineage of leptin specific target cells will be further delineated and the functional role of leptin in hematopoiesis will be investigated. Information obtained from this Phase 1 research will indicate the feasability of utilizing leptin as a therpeutic agent for the ex vivo expansion of trasnplantable progenitor cells and in vivo to accelerate recovery after transplantation.

IC Name

• Activity

  R43

• Administering IC

  HL

• Application Type

  1

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

• Sub Project Total Cost

• ARRA Funded

• CFDA Code

  839

• Ed Inst. Type

• Funding ICs

• Funding Mechanism

• Study Section

  ZRG2

• Study Section Name

• Organization Name

  ICOGENEX CORPORATION

• Organization Department

• Organization DUNS

  836856351

• Organization City

  SEATTLE

• Organization State

  WA

• Organization Country

  UNITED STATES

• Organization Zip Code

  98103

• Organization District

  UNITED STATES